PubRank

A J Baillie

Author PubWeight™ 24.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol 1988 1.33
2 Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997 1.18
3 The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol 1985 1.15
4 Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery. Antimicrob Agents Chemother 1983 1.09
5 The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur J Immunol 1989 1.05
6 Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol Cell Endocrinol 2002 1.04
7 Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol 1989 1.03
8 Production and actions of inhibin and activin during folliculogenesis in the rat. Mol Cell Endocrinol 2001 1.00
9 Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol 1988 0.99
10 Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother 1998 0.97
11 Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann Trop Med Parasitol 1992 0.95
12 Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J Drug Target 1995 0.92
13 Ovarian estrogen receptor alpha and beta mRNA expression: impact of development and estrogen. Mol Cell Endocrinol 1999 0.92
14 Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 2003 0.89
15 Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol 1998 0.88
16 Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol 1986 0.87
17 The distribution of free and non-ionic vesicular sodium stibogluconate in the dog. J Drug Target 1993 0.86
18 Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse. Exp Parasitol 1989 0.84
19 Investigating differential symptom profiles in major depressive episode with and without generalized anxiety disorder: true co-morbidity or symptom similarity? Psychol Med 2009 0.81
20 Inhibition of mobility of Tetrahymena pyriformis by certain new local anaesthetics: an alternative in vitro approach to drug screening. Pharmazie 1993 0.79
21 Genetic control of drug-induced recovery from murine visceral leishmaniasis. J Pharm Pharmacol 1993 0.79
22 Carrageenans and the proteolytic activity of human gastric secretion. J Pharm Pharmacol 1967 0.78
23 Lyophilization of unit dose pharmaceutical dosage forms. Drug Dev Ind Pharm 2003 0.77
24 Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin. Ann Trop Med Parasitol 1989 0.76
25 Activation of the fibrinolytic enzyme system in laboratory animals and in man. A comparative study. Thromb Diath Haemorrh 1971 0.76
26 The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol 1999 0.75
27 Proceedings: Modification of trypsin activity by anti-inflammatory drugs. J Pharm Pharmacol 1974 0.75
28 Size and stability of liposome suspensions measured by photon correlation spectroscopy [proceedings]. J Pharm Pharmacol 1979 0.75
29 Peptic inhibition by macroanions. J Pharm Pharmacol 1968 0.75
30 Proceedings: Cationic inhibition of pepsin with polysines. J Pharm Pharmacol 1975 0.75
31 Patch testing for nickel allergy. The influence of the vehicle on the response rate to topical nickel sulphate. Contact Dermatitis 1985 0.75
32 Wet mass shear strength and tablet dissolution [proceedings]. J Pharm Pharmacol 1978 0.75
33 Quantification of uptake of liposomal carboxyfluorescein by professional phagocytes in-vitro. A flow microfluorimetric study on the J774 murine macrophage cell line. J Pharm Pharmacol 1984 0.75
34 Proceedings: Activation and inhibition of trypsin digestion of fibrin by sodium flufenamate. J Pharm Pharmacol 1973 0.75
35 Characteristics of clients receiving treatment in Australian drug and alcohol agencies: a national census. Drug Alcohol Rev 1992 0.75
36 Skin reflectance measurements of patch test responses. Contact Dermatitis 1986 0.75
37 Proceedings: Inhibition of tryptic activity by a gastric peptide. J Pharm Pharmacol 1975 0.75
38 The effects of some synthetic compounds on in vitro fibrinolytic activity measured by different methods and the relevance to activity in vivo. Thromb Diath Haemorrh 1972 0.75
39 An in-vitro model of intracellular bacterial infection using the murine macrophage cell line J774.2. J Pharm Pharmacol 1984 0.75
40 Macroanionic inhibition of peptic activity by high and low molecular weight macroanions. Nature 1968 0.75
41 Conductivity changes during enzyme inhibitor interaction [proceedings]. J Pharm Pharmacol 1978 0.75